In the phase III, GIM-2 study that was presented by Del Mastro el al, #dose_dense chemotherapy significantly improved DFS and OS compared with standard schedules in the adjuvant treatment of early #breast_cancer. The Italian study randomized 2091 patients in a 2x2 design to dose dense versus standard schedule with or without 5 Fluorouracil. These results are consistent with the EBCTCG meta-analysis regarding superiority of dose dense strategy both in ER+ and ER- patients.
In the phase III, GIM-2 study that was presented by Del Mastro el al, #dose_dense chemotherapy significantly improved DFS and OS compared with standard schedules in the adjuvant treatment of early #breast_cancer. The Italian study randomized 2091 patients in a 2x2 design to dose dense versus standard schedule with or without 5 Fluorouracil. These results are consistent with the EBCTCG meta-analysis regarding superiority of dose dense strategy both in ER+ and ER- patients.
.png)